Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia

Phase 2 Terminated 92 enrolled Anbics Management-Services Ag Swiss National Science Foundation · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the clinical efficacy of azithromycin, used as a quorum-sensing blocker, when compared to placebo for preventing or delaying the occurrence of pneumonia in ventilated patients colonized with Pseudomonas aeruginosa.

Timeline

Start: 2003-04
Primary completion: 2005-10
Completion: 2005-10

Outcome

Outcome not reported

Stopped (Business): “The sponsor decided to stop the study prematurely because of financial issues”

Publications

Kohler T, Perron GG, Buckling A, van Delden C. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 2010 May 6;6(5):e1000883. doi: 10.1371/journal.ppat.1000883.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azithromycin	Small molecule	300 mg	Intravenous